Navigation Links
Genetic Marker for Aggressive Prostate Cancer Found

Variant could be used to guide treatment, researchers suggest

MONDAY, Jan. 11 (HealthDay News) -- A focused search of the entire human genome has found a genetic variant associated with the aggressiveness of prostate cancer, in a discovery that marks an important first step toward singling out cancers that need intensive treatment from those that can simply be left alone.

"It is a proof of principle to show that there are variants in the genome that influence the different kinds of prostate cancer," said Dr. Jianfeng Xu, a professor of epidemiology and cancer biology at Wake Forest University Baptist Medical Center, and leader of a team reporting the finding online in the Jan. 11-15 early edition of the Proceedings of the National Academy of Sciences.

A marker for aggressiveness of prostate cancer is sorely needed, cancer specialists agree. While many men are diagnosed with prostate cancer -- it accounts for one-fourth of all cancer diagnoses in the United States -- a large percentage of those malignancies grow so slowly that they never are life-threatening. Because there is now no way of identifying so-called "indolent" prostate cancers, many men are overtreated, because they and their physicians prefer to be on the safe side.

The new genetic variant cannot be such a marker by itself, Xu said. "One SNP has limited ability, but a panel of SNPs would be useful to identify men who have high risk for aggressive prostate cancers," he said.

An SNP -- single-nucleotide polymorphism -- is a variation in the long string of DNA molecules that make up the genome that determines all human traits.

Xu and his colleagues looked for SNPs in the genomes of 4,829 men with aggressive prostate cancers -- defined as having more disorderly structure and growing beyond the prostate gland -- and 12,205 with slow-growing cancers. They found one SNP that was associated with a 25 percent greater risk of developing aggressive disease.

Several dozen genetic variants have been linked to a greater risk of developing prostate cancer, but this is the first to be associated with aggressiveness of the disease, Xu said.

"The entire field has a long way to go, but this is an important first step," he said.

One indication of the distance to be traveled is the finding that the variant is located in a part of the genome where no gene has been found. This is not an uncommon finding, Xu explained, since many of the risk-associated variants are not in genes. "Our understanding of how the genome works is very limited," he said.

Still, much can be accomplished with what is known, with appropriate changes in strategy, Xu noted. Until now, the focus in prostate cancer has been on finding variants that affect the risk of developing the malignancy. "If you use that approach, it is difficult to distinguish aggressive from non-aggressive cancers," he said. "If you compare two groups of patients, one with indolent disease, one not, you are more likely to find those variants."

A second study comparing the genomes of 1,000 men with aggressive prostate cancer and an equal number with the indolent form of the disease is under way, with results expected to be published later this year, Xu added. The hope is to find a series of variants that might eventually be used by physicians in a screening test to help determine when more than watchful waiting is needed for prostate cancer, he said.

"Our work is too early to say whether it will have a clinical impact," said William B. Isaacs, a professor of urology and oncology at Johns Hopkins Medical Institutions, and a member of the research team. "It wont change the approach to identifying men with the aggressive form of prostate cancer. But this demonstrates that such markers do exist, and by studying them we may be able to understand the biological pathways that contribute to making prostate cancer more aggressive."

"Its not earth-shattering," said William Phelps, program director for translational and preclinical cancer research at the American Cancer Society, "but rather a modest advance over previous genetic analyses, a move in the right direction. Its real importance is trying to focus us on what we can do to develop a protocol to identify aggressive from nonaggressive prostate cancers."

More information

Learn what you need to know about prostate cancer from the U.S. National Cancer Institute.

SOURCES: Jianfeng Xu, M.D., Ph.D., professor, epidemiology and cancer biology, Wake Forest University Baptist Medical Center, Winston-Salem, N.C.; William B. Isaacs, Ph.D., professor, urology and oncology, Johns Hopkins Medical Institutions, Baltimore; William Phelps, Ph.D., program director, translational and preclinical cancer research, American Cancer Society, Atlanta; Jan. 11-15, 2010, Proceedings of the National Academy of Sciences, online

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Genetic variant associated with aggressive form of prostate cancer
2. Biologists develop efficient genetic modification of human embryonic stem cells
3. Adding a genetic supertool
4. Chicago Cancer Genome Project studies genetics of 1,000 tumors
5. U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines
6. Genetic Test May Someday Help Spot Breast Cancer
7. New License Agreement with University of Colorado Gives Viral Genetics, Inc., Right to Develop Cancer Therapies
8. Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patients
9. Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York
10. Genetic studies reveal new causes of severe obesity in childhood
11. Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
Post Your Comments:
(Date:11/25/2015)... BROOK, Ill. (PRWEB) , ... November 25, 2015 ... ... larger and potentially more aggressive than those found on mammography, according to a ... MRI findings of additional cancers not seen on mammography may necessitate a change ...
(Date:11/25/2015)... ... 2015 , ... As part of a global movement to ... together who want to combine talents and resources to help create sustainable communities ... The non-profit launched its first major fundraiser on November 6, 2015 at Bent ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/25/2015)... -- The total global healthcare industry is expected to grow at ... America has the highest projected growth at 12.7%, ... ), is second with growth projected at 11.5%. ... expenditure. In 2013-2014, total government funded healthcare was nearly 68%. ... 41.2% in 2013-2014. In real terms, out of pocket expenditure ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: